Unknown × Interventional × Myelodysplastic Syndromes × Clear all Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Phase 1 Unknown
24 enrolled
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Phase 1 Unknown
112 enrolled
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Phase 1 Unknown
198 enrolled
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Phase 1/2 Unknown
69 enrolled
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
Phase 1/2 Unknown
22 enrolled
MoTD
Phase 2 Unknown
400 enrolled
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Phase 1 Unknown
48 enrolled
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Phase 1 Unknown
32 enrolled
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 1/2 Unknown
126 enrolled
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT
Phase 2 Unknown
70 enrolled
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
Phase 1/2 Unknown
120 enrolled
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Phase 1 Unknown
38 enrolled
Enhanced Palliative Care in MDS and AML
Phase NA Unknown
90 enrolled
Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1 Unknown
73 enrolled
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT
Phase 1/2 Unknown
20 enrolled
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 1 Unknown
58 enrolled
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
Phase 2/3 Unknown
180 enrolled
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
Phase 1/2 Unknown
20 enrolled
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Phase 1/2 Unknown
100 enrolled
MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies
Phase NA Unknown
300 enrolled
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Phase 1 Unknown
40 enrolled
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
Phase 2 Unknown
5 enrolled
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Unknown
102 enrolled 12 charts
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Phase 2 Unknown
50 enrolled
CALVI
Phase 3 Unknown
140 enrolled
Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 1/2 Unknown
5 enrolled
PRO-DLI
Phase 2 Unknown
124 enrolled
NK Cells in Cord Blood Transplantation
Phase 1 Unknown
13 enrolled
AML18
Phase 2/3 Unknown
1,600 enrolled
ToTem
Phase 1 Unknown
18 enrolled
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Phase 1/2 Unknown
65 enrolled
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC
Phase 3 Unknown
100 enrolled
ProT4
Phase 2 Unknown
114 enrolled
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation
Phase 2 Unknown
40 enrolled
TRANSATRA
Phase 1/2 Unknown
60 enrolled
MacHaploMud
Phase 3 Unknown
344 enrolled
AML
Phase 1/2 Unknown
105 enrolled
PANOBEST
Phase 1/2 Unknown
62 enrolled
GLIDE
Phase 1/2 Unknown
20 enrolled
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)
Phase 1 Unknown
10 enrolled
Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation
Phase 2 Unknown
40 enrolled
BBMPI03
Phase 1 Unknown
4 enrolled
PODAC
Phase 1 Unknown
19 enrolled
Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine
Phase NA Unknown
35 enrolled
GFM-Chimio-Rev
Phase 2 Unknown
85 enrolled
B-cell therapy
Phase 1/2 Unknown
15 enrolled
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
Phase 2 Unknown
25 enrolled
T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Phase 1/2 Unknown
16 enrolled
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
Phase NA Unknown
35 enrolled